Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Mallinckrodt
Boehringer Ingelheim
McKinsey
Johnson and Johnson

Last Updated: February 4, 2023

Details for Patent: 6,887,459


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 6,887,459
Title: Aerosol composition comprising formoterol
Abstract:The use of a dry powder comprising (A) formoterol, or a pharmaceutically acceptable salt or solvate thereof, or solvate of said salt, and (B) a pharmaceutically acceptable particulate diluent or carrier in an amount of from 400 .mu.g to 5000 .mu.g per .mu.g of (A) for the preparation of an inhalable medicament for the treatment of chronic obstructive pulmonary disease.
Inventor(s): Haeberlin; Barbara (Muenchenstein, CH)
Assignee: Novartis, AG (Basel, CH)
Application Number:10/148,043
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 6,887,459

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,887,459

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9928311Nov 30, 1999
PCT Information
PCT FiledNovember 28, 2000PCT Application Number:PCT/EP00/11894
PCT Publication Date:June 07, 2001PCT Publication Number: WO01/39745

International Family Members for US Patent 6,887,459

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2837401 See Plans and Pricing
Australia 769765 See Plans and Pricing
Brazil 0015908 See Plans and Pricing
Canada 2389349 See Plans and Pricing
China 1399540 See Plans and Pricing
Czech Republic 20021850 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Harvard Business School
Mallinckrodt
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.